ZOETIS INC (ZTS) Stock Price, Quote, News and Overview
NYSE:ZTS - New York Stock Exchange, Inc. - US98978V1035 - Common Stock
ZTS Quote and Key Statistics
ZOETIS INC
NYSE:ZTS (1/22/2025, 8:04:00 PM)
After market: 166.63 0 (0%)166.63
-0.9 (-0.54%)
ZTS Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 26.55% | ||
| ROA | 16.93% | ||
| ROE | 46.43% | ||
| Debt/Equity | 1.26 |
ZTS Performance and Technical Analysis
ZTS Ownership and Analysts
ZTS Latest News and Analysis
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
These companies lead their respective markets, making them must-haves for buy-and-hold dividend investors.
March 21st Options Now Available For Zoetis (ZTS)
YieldBoost ZTS To 8.2% Using Options
Is Zoetis Inc. (NYSE: ZTS) Overvalued? Or Is It Worth Buying Now?
/PRNewswire/ -- Zoetis's recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory...
About ZTS
Company Profile
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The company is headquartered in Parsippany, New Jersey and currently employs 14,100 full-time employees. The company went IPO on 2013-02-01. The firm is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The firm operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. The company directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The company is engaged in commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
Company Info
ZOETIS INC
10 Sylvan Way
Parsippany NEW JERSEY 07054 US
CEO: Kristin C. Peck
Employees: 14100
Company Website: https://www.zoetis.com/
Investor Relations: https://investor.zoetis.com
Phone: 19738227000
ZTS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 74.14 | 715.77B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.22 | 357.84B | ||
| JNJ | JOHNSON & JOHNSON | 14.19 | 349.75B | ||
| MRK | MERCK & CO. INC. | 16.08 | 242.04B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.9 | 211.49B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.16 | 196.27B | ||
| PFE | PFIZER INC | 10.08 | 147.40B | ||
| SNY | SANOFI-ADR | 12.38 | 129.15B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.79 | 115.79B | ||
| GSK | GSK PLC-SPON ADR | 8.17 | 68.21B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.48 | 40.87B | ||
| TEVA | TEVA PHARMACEUTICAL-SP ADR | 7.92 | 24.94B |